

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



# 石四藥集團有限公司 SSY Group Limited

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2005)**

## **VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT**

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group has obtained the approval for drug production and registration for Azithromycin for Suspension from the National Medical Products Administration of China, being regarded as passing the consistency evaluations, and is the first of such approval for the PRC entities. Azithromycin for Suspension is a second-generation macrolide antibiotic, which is mainly used in treatment of lower respiratory tract infections such as bronchitis and pneumonia, skin and soft tissue infections, acute otitis media and upper respiratory tract infections such as sinusitis, pharyngitis and tonsillitis which are caused by susceptible bacteria.

In addition, the Board is also pleased to announce that the Group’s Argatroban has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Argatroban is a new generation anticoagulant belonging to a small molecule direct thrombin inhibitor, which is mainly used in clinical treatment of peripheral artery occlusive disease, and in prevention or treatment of thrombosis in arteries.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board

**Chow Hing Yeung**

*Executive Director and Company Secretary*

Hong Kong, 5 September 2022

*As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo and Mr. Chow Hing Yeung as executive Directors, Mr. Feng Hao as non-executive Director and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.*